Immune Tolerance Network   

A clinical research consortium sponsored by NIAID and JDRF

About Us

RETAIN is a clinical research study conducted by the Immune Tolerance Network together with researchers from other clinical research centers. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIH funded), with support from the Juvenile Diabetes Research Foundation. 

Immune Tolerance Network

The Immune Tolerance Network (ITN) is an international research consortium funded by the National Institute of Allergy and Infectious Diseases and the Juvenile Diabetes Research Foundation International. The ITN develops and conducts clinical studies of immune tolerance therapies — highly targeted treatments designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. The ITN consortium is led by several institutions, including University of California, San Francisco; Benaroya Research Institute at Virginia Mason, Seattle; and Beth Israel Deaconess Medical Center, Boston. ›

National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests and other technologies that have improved the health of millions of people in the United States and around the world. ›

Juvenile Diabetes Research Foundation

JDRF was founded in 1970 by the parents of children with type 1 diabetes - a disease that strikes children, adolescents, and adults suddenly, makes them insulin dependent for life, and carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.16 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. ›